+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Cervical Cancer

  • ID: 4421374
  • Report
  • March 2021
  • Region: Global
  • Datamonitor Healthcare
This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.

Approved drugs for cervical cancer target vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, and reactive oxygen species/free radicals. The majority of these therapies are administered via the intravenous route.

The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with three drugs in the NDA/BLA stage.

Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, intravesical, and intranasal formulations.

High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase III trial results for Libtayo and Imfinzi, and expected PDUFA dates for biosimilar bevacizumab (Mylan/Biocon) and tisotumab vedotin.

The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 43%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.

The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.

Roche has the highest number of completed clinical trials for cervical cancer, with 16 trials.

AstraZeneca leads industry sponsors with the highest overall number of clinical trials for cervical cancer.
Note: Product cover images may vary from those shown

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
  • Balstilimab for Cervical Cancer (September 18, 2020)
  • Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
  • GX-188E for Cervical Cancer (April 27, 2020)
  • Multiple Drugs for Cervical Cancer (February 20, 2020)
  • HLX10 for Cervical Cancer (September 12, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Agenus Kicks Off Rolling BLA For Balstilimab
  • Samsung Bioepis Receives EU Bevacizumab Approval
  • Biosimilar Avastin Is Launched In India
  • Mylan Reveals FDA Goal Date For Bevacizumab

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Biomm Backs Bio-Thera’s Brazilian Bevacizumab
  • Betta Gains China-Plus Rights To Two Agenus Oncology Drugs

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of cervical cancer, 2017–26
Figure 2: Overview of pipeline drugs for cervical cancer in the US
Figure 3: Pipeline drugs for cervical cancer, by company
Figure 4: Pipeline drugs for cervical cancer, by drug type
Figure 5: Pipeline drugs for cervical cancer, by classification
Figure 6: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II - innovaTV 204
Figure 7: Balstilimab for Cervical Cancer (September 18, 2020): Phase II - RaPiDS (+/- AGEN1884, 2nd Line)
Figure 8: Tisotumab Vedotin for Cervical Cancer (June 29, 2020): Phase II - innovaTV 204
Figure 9: GX-188E for Cervical Cancer (April 27, 2020): Phase Ib/IIa - w/Pembrolizumab (Korea)
Figure 10: Multiple Drugs for Cervical Cancer (February 20, 2020): Phase II - RaPiDS
Figure 11: Key upcoming events in cervical cancer
Figure 12: Probability of success in the solid tumors pipeline
Figure 13: Clinical trials in cervical cancer
Figure 14: Top 10 drugs for clinical trials in cervical cancer
Figure 15: Top 10 companies for clinical trials in cervical cancer
Figure 16: Trial locations in cervical cancer
Figure 17: Cervical cancer trials status
Figure 18: Cervical cancer trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of cervical cancer, 2017–26
Table 2: Marketed drugs for cervical cancer
Table 3: Pipeline drugs for cervical cancer in the US
Table 4: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
Table 5: Balstilimab for Cervical Cancer (September 18, 2020)
Table 6: Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
Table 7: GX-188E for Cervical Cancer (April 27, 2020)
Table 8: Multiple Drugs for Cervical Cancer (February 20, 2020)
Table 9: HLX10 for Cervical Cancer (September 12, 2019)
Table 10: Historical global sales, by drug ($m), 2015–19
Table 11: Forecasted global sales, by drug ($m), 2021–25

Note: Product cover images may vary from those shown
Adroll
adroll